medRxiv PreprintsInternational19 November 2026
Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection on biopsy were assessed in the Million Veteran Program (MVP), with external validation in the Prostate Cancer Prevention Trial (PCPT). Among 428,512 MVP participants, high versus low P-CARE risk was associated with increased hazards of treatment (HR 3.32) and metastasis (HR 3.32). Among men whose base
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.